Literature DB >> 28719856

Contribution of Kupffer cells to liposome accumulation in the liver.

Emma Samuelsson1, Haifa Shen2, Elvin Blanco1, Mauro Ferrari3, Joy Wolfram4.   

Abstract

The liver is a major barrier for site-specific delivery of systemically injected nanoparticles, as up to 90% of the dose is usually captured by this organ. Kupffer cells are thought to be the main cellular component responsible for nanoparticle accumulation in the liver. These resident macrophages form part of the mononuclear phagocyte system, which recognizes and engulfs foreign bodies in the circulatory system. In this study, we have compared two strategies for reducing nanoparticle accumulation in the liver, in order to investigate the specific contribution of Kupffer cells. Specifically, we have performed a comparison of the capability of pegylation and Kupffer cell depletion to reduce liposome accumulation in the liver. Pegylation reduces nanoparticle interactions with all types of cells and can serve as a control for elucidating the role of specific cell populations in liver accumulation. The results indicate that liposome pegylation is a more effective strategy for avoiding liver uptake compared to depletion of Kupffer cells, suggesting that nanoparticle interactions with other cells in the liver may also play a contributing role. This study highlights the need for a more complete understanding of factors that mediate nanoparticle accumulation in the liver and for the exploration of microenvironmental modulation strategies for reducing nanoparticle-cell interactions in this organ.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Kupffer cells; Liver; Macrophages; Mononuclear phagocyte system; Nanoparticles; Pegylation

Mesh:

Substances:

Year:  2017        PMID: 28719856      PMCID: PMC5645238          DOI: 10.1016/j.colsurfb.2017.07.014

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  31 in total

Review 1.  The journey of a drug-carrier in the body: an anatomo-physiological perspective.

Authors:  Nicolas Bertrand; Jean-Christophe Leroux
Journal:  J Control Release       Date:  2011-10-06       Impact factor: 9.776

2.  A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.

Authors:  Bronwyn Scott; Jianliang Shen; Sara Nizzero; Kathryn Boom; Stefano Persano; Yu Mi; Xuewu Liu; Yuliang Zhao; Elvin Blanco; Haifa Shen; Mauro Ferrari; Joy Wolfram
Journal:  Pharmacol Res       Date:  2016-07-06       Impact factor: 7.658

3.  Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinase-overexpressing tumor xenograft model.

Authors:  Ying Chau; Natalie M Dang; Frederick E Tan; Robert Langer
Journal:  J Pharm Sci       Date:  2006-03       Impact factor: 3.534

4.  Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead.

Authors:  S M Moghimi; A J Andersen; S H Hashemi; B Lettiero; D Ahmadvand; A C Hunter; T L Andresen; I Hamad; J Szebeni
Journal:  J Control Release       Date:  2010-04-11       Impact factor: 9.776

Review 5.  Anti-PEG immunity: emergence, characteristics, and unaddressed questions.

Authors:  Qi Yang; Samuel K Lai
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-02-23

Review 6.  Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications.

Authors:  N Van Rooijen; A Sanders
Journal:  J Immunol Methods       Date:  1994-09-14       Impact factor: 2.303

7.  Liposome-encapsulated dichloromethylene diphosphonate induces macrophage apoptosis in vivo and in vitro.

Authors:  M Naito; H Nagai; S Kawano; H Umezu; H Zhu; H Moriyama; T Yamamoto; H Takatsuka; Y Takei
Journal:  J Leukoc Biol       Date:  1996-09       Impact factor: 4.962

8.  Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process.

Authors:  I Hamad; A C Hunter; J Szebeni; S M Moghimi
Journal:  Mol Immunol       Date:  2008-10-11       Impact factor: 4.407

9.  Hesperetin Liposomes for Cancer Therapy.

Authors:  Joy Wolfram; Bronwyn Scott; Kathryn Boom; Jianliang Shen; Carlotta Borsoi; Krishna Suri; Rossella Grande; Massimo Fresta; Christian Celia; Yuliang Zhao; Haifa Shen; Mauro Ferrari
Journal:  Curr Drug Deliv       Date:  2016       Impact factor: 2.565

10.  The Macrophage-depleting Agent Clodronate Promotes Durable Hematopoietic Chimerism and Donor-specific Skin Allograft Tolerance in Mice.

Authors:  Zhanzhuo Li; Xin Xu; Xingmin Feng; Philip M Murphy
Journal:  Sci Rep       Date:  2016-02-26       Impact factor: 4.379

View more
  27 in total

1.  Clinical Cancer Nanomedicine.

Authors:  Joy Wolfram; Mauro Ferrari
Journal:  Nano Today       Date:  2019-03-06       Impact factor: 20.722

2.  64Cu-labeled melanin nanoparticles for PET/CT and radionuclide therapy of tumor.

Authors:  Huijun Zhou; Qing Zhang; Yan Cheng; Lili Xiang; Guohua Shen; Xiaoai Wu; Huawei Cai; Daifeng Li; Hua Zhu; Ruiping Zhang; Lin Li; Zhen Cheng
Journal:  Nanomedicine       Date:  2020-06-20       Impact factor: 5.307

Review 3.  Organotropic drug delivery: Synthetic nanoparticles and extracellular vesicles.

Authors:  Sara Busatto; Anthony Pham; Annie Suh; Shane Shapiro; Joy Wolfram
Journal:  Biomed Microdevices       Date:  2019-04-15       Impact factor: 2.838

Review 4.  Lipoprotein-based drug delivery.

Authors:  Sara Busatto; Sierra A Walker; Whisper Grayson; Anthony Pham; Ming Tian; Nicole Nesto; Jacqueline Barklund; Joy Wolfram
Journal:  Adv Drug Deliv Rev       Date:  2020-08-11       Impact factor: 15.470

5.  "Petal-like" size-tunable gold wrapped immunoliposome to enhance tumor deep penetration for multimodal guided two-step strategy.

Authors:  Yanan Li; Wenting Song; Yumin Hu; Yun Xia; Zhen Li; Yang Lu; Yan Shen
Journal:  J Nanobiotechnology       Date:  2021-09-27       Impact factor: 10.435

Review 6.  Extracellular vesicles as delivery systems at nano-/micro-scale.

Authors:  Peiwen Fu; Jianguo Zhang; Haitao Li; Michael Mak; Wenrong Xu; Zhimin Tao
Journal:  Adv Drug Deliv Rev       Date:  2021-08-03       Impact factor: 15.470

Review 7.  Going even smaller: Engineering sub-5 nm nanoparticles for improved delivery, biocompatibility, and functionality.

Authors:  Manman Xie; Yaolin Xu; Jing Huang; Yuancheng Li; Liya Wang; Lily Yang; Hui Mao
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-05-20

8.  Macrophage depletion increases target specificity of bone-targeted nanoparticles.

Authors:  Marian A Ackun-Farmmer; Baixue Xiao; Maureen R Newman; Danielle S W Benoit
Journal:  J Biomed Mater Res A       Date:  2021-07-28       Impact factor: 4.396

9.  A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery.

Authors:  Joy Wolfram; Sara Nizzero; Haoran Liu; Feng Li; Guodong Zhang; Zheng Li; Haifa Shen; Elvin Blanco; Mauro Ferrari
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

10.  Temporary suppression the sequestrated function of host macrophages for better nanoparticles tumor delivery.

Authors:  Jifu Hao; Te Han; Meixiang Wang; Qiannan Zhuang; Xiaodan Wang; Jianguo Liu; Yongan Wang; Hua Tang
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.